Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T22:38:39.521Z.
Calculation as of: 2026-10-06T22:38:39.521Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69957a8c264286ff6eaa706b48c8270e863bf40c8b9bfd4321b5f2d082882a11
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$215.07M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$216.91M
PS Ratio
9.67
TTM Avg
19.23
3Y Avg
17.60
5Y Avg
17.60
Market Cap
$210.98M
PS Ratio
7814.17
TTM Avg
10075.42
3Y Avg
5826.11
5Y Avg
3526.58
Market Cap
$218.30M
PS Ratio
14.54
TTM Avg
5.37
3Y Avg
8939.29
5Y Avg
7197.79
Market Cap
$210.41M
PS Ratio
44.90
TTM Avg
28.94
3Y Avg
12.07
5Y Avg
12.54
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sionna Therapeutics, Inc. (SION) | $214.46M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 1.66 | 3.22 | 3.89 | 3.24 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | N/A | N/A | N/A | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | 9.67 | 19.23 | 17.60 | 17.60 |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | 7814.17 | 10075.42 | 5826.11 | 3526.58 |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | 14.54 | 5.37 | 8939.29 | 7197.79 |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.41M | 44.90 | 28.94 | 12.07 | 12.54 |
| Compugen Ltd. (CGEN)vs › | $209.91M | 2.84 | 9.59 | 7.89 | 14.57 |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
| Profound Medical Corp. (PROF)vs › | $220.93M | 11.62 | 13.79 | 19.84 | 21.38 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-02 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-12 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
